This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of other and ill-defined sites (cancer of unknown primary)Malignant Neoplasm of Other and Ill-defined Sites

Contents
A. Classification codes | B. Synonyms | C. Adult onset
1. History | 2. Causes | 3. Genetics | 4. General epidemiology | 5. Pathophysiology
6. Symptoms | 7. Signs | 8. Screening | 9. Diagnosis | 10. Treatment
11. Prognosis | 12. Prevention | 13. References
ItemDetails
A. Classification codesICD-10: C76 | Special Copayment Reduction: V193 | Copayment 5% (for 5 years from the date of cancer patient registration)
C76.0 head, C76.1 thorax, C76.2 abdomen, C76.3 pelvis, C76.4 upper limb, C76.5 lower limb, C76.7 other, C76.8 overlapping
B. SynonymsCancer of unknown primary, carcinoma of unknown primary origin, malignant neoplasm of ill-defined sites, Cancer of Unknown Primary (CUP), Carcinoma of Unknown Primary, Occult primary tumor, CUP syndrome
C. Adult onsetVery high — occurs mainly in adults in their 60s–70s; rare in young adults

1. History

Clinical recognition of cancer of unknown primary (CUP) became systematized from the mid-20th century. The clinical situation in which metastatic cancer is diagnosed but the primary lesion cannot be found has long been a medical puzzle, and before the 1970s it was mostly described simply as "metastatic cancer of unknown origin." From the 1970s, advances in immunohistochemistry (IHC) made it possible to subclassify the histologic types of CUP, and adenocarcinoma was confirmed as the most common histologic type. In the 1980s–90s, the accuracy of CUP diagnosis improved as IHC application of epithelial antigens (CK, EpCAM) and histotype-specific markers (PSA, TTF-1, HER2, etc.) expanded.

Since the 2000s, the clinical introduction of PET-CT has contributed to the additional identification of the primary lesion in about 30–40% of CUP patients. In the 2010s, the emergence of next-generation sequencing (NGS) and comprehensive genomic profiling panels (CGP) made molecular tissue-of-origin profiling of CUP possible, and site-directed therapy based on the predicted primary site began to be applied clinically. Molecular tissue-of-origin assays such as CancerSEEK, Decipher and CancerTYPE ID are used at the research and clinical stages. The 2022 ESMO clinical practice guidelines included comprehensive molecular profiling in CUP at the level of a recommendation.

2. Causes

The biological nature of cancer of unknown primary (CUP) remains incompletely understood. CUP is understood not as a distinct primary tumor but as a tumor-biological state in which the metastatic phenotype predominates over the primary lesion. The hypothesis of spontaneous regression of the primary lesion (primary site regression) has been proposed: in some cases the primary lesion is small and has been eliminated by the immune system, or regression occurs within the tumor itself, making it clinically undetectable. Another explanation is that selection pressure for a highly metastatic phenotype expands metastasis-dominant clones, leaving the primary lesion at a growth disadvantage.

CUP has no single cause; it is a situation in which malignancies of various primary organs ultimately present without an identified primary lesion at the time of diagnosis. Reported risk factors include smoking (associated with increased CUP risk), older age and male sex. In molecular tissue-of-origin analyses, the most common predicted primary organs of CUP are the lung, colon, pancreas, stomach, kidney and liver, which provides important clues for understanding the pathogenesis of CUP. Specific CUP subsets—squamous cell carcinoma of the neck (CUP), squamous cell carcinoma of the inguinal region, peritoneal adenocarcinomatosis (women), and solitary bone metastasis—are special groups whose link to a primary lesion is clearer and whose prognosis is relatively favorable.

3. Genetics

The genomics of CUP is rapidly becoming systematized with advances in comprehensive genomic profiling (CGP). Clinically meaningful somatic mutations are found in about 85% of CUP patients. The most common molecular abnormalities are those shared across many cancer types, such as TP53 mutations, KRAS mutations, CDKN2A loss, PIK3CA mutations, ERBB2 (HER2) amplification and MET alterations. Of these, alterations that can be therapeutic targets of currently approved drugs are found in 13–64% of cases.

MSI-H (microsatellite instability-high) and dMMR (mismatch repair deficiency): found in about 2–5% of CUP; pembrolizumab is approved in a tumor-agnostic manner. TMB-H (tumor mutational burden-high, ≥10 mut/Mb): a tumor-agnostic indication for pembrolizumab. NTRK fusion: found in about 1–3% of CUP; candidates for larotrectinib/entrectinib. RET fusion: a target of selpercatinib. Molecular tissue-of-origin profiling predicts the primary organ through analysis of RNA expression patterns and DNA methylation patterns, and is used on this basis to select site-directed therapy.

4. General epidemiology

Cancer of unknown primary (CUP) is a frequent clinical situation, accounting for about 2–5% of all cancer diagnoses worldwide. However, with advances in PET-CT, high-sensitivity CT/MRI and comprehensive molecular profiling, the proportion has recently been declining to below 1%. The global annual incidence was about 2–15 per 100,000 population (varying by region), but has been declining to 5.8/100,000 since 2014. Because CUP is already metastatic at diagnosis, the treatment goal in most patients is prolonging survival and maintaining quality of life rather than cure.

Distribution by histologic type: adenocarcinoma is the most common at 42.3%, followed by unclassified neoplasms 28.1%, undifferentiated carcinoma 16.6%, squamous cell carcinoma under 7%, and neuroendocrine carcinoma under 7%. The incidence of CUP in Korea is not tallied separately, but it is estimated that several hundred cases of CUP are diagnosed annually at major cancer centers in Korea. Incidence is higher in older adults, men and smokers. The median age at diagnosis is in the 60s–70s, and most patients already have metastases to multiple organs.

5. Pathophysiology

The pathogenesis of cancer of unknown primary has unique aspects that differ from general cancer biology. The most widely accepted hypothesis is the primary site regression and metastasis-dominance theory. Accumulation of oncogenic mutations in normal cells → formation of the primary lesion → selection of clones with strong metastatic potential already at an early stage → growth arrest or disappearance of the primary lesion (immune elimination, loss of blood supply, autonecrosis) → clinically dominant growth of metastatic lesions. Through this, the primary lesion remains at a size undetectable on imaging at the time of diagnosis or regresses completely.

At the molecular level, the gene expression profile of CUP is mostly similar to that of common carcinomas, but high expression of genes related to EMT (epithelial-mesenchymal transition) and angiogenesis in particular has been reported. In addition, in DNA methylation profile analysis, CUP tends to be classified into clusters of specific primary-organ carcinomas, suggesting that molecular traces of the hidden primary lesion remain in the metastatic lesions. The true reason the primary lesion is not identified in some CUP is presumed to be that the primary cancer exists at a very small scale (<5mm) or has disappeared through immune elimination.

6. Symptoms

Symptoms of cancer of unknown primary are highly variable and nonspecific depending on the location of metastatic lesions and tumor burden. The most common presenting complaint is lymphadenopathy (cervical, supraclavicular, inguinal lymph nodes). Other common symptoms include bone pain (bone metastasis), dyspnea and chest pain (pleural effusion, lung metastasis), abdominal pain and distension (peritoneal metastasis, ascites, liver metastasis), jaundice (liver or biliary involvement), and neurological symptoms (brain metastasis, spinal cord compression). Systemic symptoms—fever, weight loss, fatigue, anorexia—are common symptoms of advanced cancer and also appear frequently in CUP.

Symptoms by histologic type: in adenocarcinoma CUP, abdominal symptoms from intra-abdominal metastasis (peritoneal adenocarcinomatosis) and refractory ascites are common. In squamous cell carcinoma CUP, when cervical lymph node metastasis predominates, neck mass and throat pain appear; when inguinal metastasis predominates, perineal and lower-limb lymphedema appear. In neuroendocrine CUP, carcinoid syndrome (facial flushing, diarrhea, dyspnea) may occur. Notably, in male CUP, when pelvic bone metastasis and prostate-specific symptoms are present, prostate cancer is strongly suspected.

7. Signs

The most common finding on physical examination is lymphadenopathy (cervical, supraclavicular, axillary, inguinal). Supraclavicular lymphadenopathy is an important clinical sign suggesting a primary lesion in the thoracic or abdominal cavity (left: Virchow's node — suggests an intra-abdominal primary). Abdominal examination may reveal hepatomegaly, an abdominal mass, and tense ascites. Neurological examination may reveal a sensory level, motor deficits and voiding dysfunction due to epidural spinal cord compression. Pleural effusion is confirmed by dullness on percussion and decreased breath sounds on auscultation.

In bone metastasis there is tenderness of the spine, pelvis, femur and other sites, and pathological fractures may occur. Skin metastases are palpated as hard subcutaneous nodules. In peritoneal carcinomatosis, ascites and symptoms of bowel obstruction (nausea, vomiting, constipation) appear. The elevation pattern of serum tumor markers (CEA, CA19-9, CA125, AFP, PSA, calcitonin, etc.) provides clues for predicting the primary organ, but is not diagnostic on its own. Jaundice (scleral icterus) and liver tenderness suggest liver metastasis.

8. Screening

There is no general population screening program for cancer of unknown primary. Because CUP is by definition diagnosed in the metastatic state, the focus of screening is not CUP itself but encouraging early detection of primary lesions through general screening programs for common primary cancers (colorectal, breast, lung, cervical, prostate cancer). Korea's National Cancer Screening Program (gastric, colorectal, liver, cervical, breast cancer) serves this purpose.

In patients with suspected or diagnosed CUP, a systematic approach to identifying the primary lesion is needed. First, basic tests include abdominal-pelvic-chest CT, mammography (women), PSA (men), fecal occult blood testing, and upper and lower endoscopy. Thereafter, FDG-PET-CT contributes to additional identification of the primary lesion in about 30–40% of CUP. Molecular profiling and molecularly directed tissue-of-origin testing are increasingly becoming part of the standard diagnostic process. MSI/dMMR and TMB testing are recommended in all CUP patients.

9. Diagnosis

CUP is diagnosed when a metastatic malignancy is confirmed but the primary lesion cannot be identified even after thorough standard workup. The diagnostic process is stepwise. Step 1: tissue biopsy—core biopsy preferred; fine-needle aspiration (FNA) is supplementary. Immunohistochemistry (IHC) on the tissue determines the tissue lineage of the cancer (adenocarcinoma, squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, lymphoma, etc.). Step 2: site-specific marker IHC—TTF-1 (lung, thyroid), CK7/CK20 combination, PAX8 (kidney, ovary), CDX2 (gastrointestinal tract), PSA (prostate), WT1 (ovary, mesothelium), calretinin (mesothelium), GATA3 (breast, bladder), AFP (liver), HMB45/Melan-A (melanoma), etc.

Step 3: imaging—chest-abdominal-pelvic CT (contrast-enhanced), FDG-PET-CT (identification of the primary lesion and assessment of systemic metastasis). Mammography and breast MRI in women; PSA in men. Step 4: comprehensive genomic profiling (CGP)—NGS-based multigene panel; MSI/TMB; molecular tissue-of-origin analysis. Endoscopy (if gastrointestinal symptoms); if the primary lesion remains unclear even after PET-CT, additional MRI or specialized endoscopy (bronchoscopy, colonoscopy). Cytology and molecular test results are integrated to complete the final CUP diagnosis and subset classification—favorable prognosis (squamous cell carcinoma, neuroendocrine, peritoneal adenocarcinomatosis in women, etc.) vs. poor prognosis (adenocarcinoma, undifferentiated carcinoma).

10. Treatment

CUP treatment consists of two axes: site-directed therapy according to histologic type and prognostic subset and empirical chemotherapy. In favorable-prognosis CUP subsets—squamous cell carcinoma of the neck (HPV-positive head and neck cancer protocol), squamous cell carcinoma of the inguinal region (anal and vulvar cancer protocol), peritoneal adenocarcinomatosis in women (ovarian cancer protocol: Taxol+carboplatin), extragonadal germ cell tumor (BEP protocol), and solitary bone metastasis or single-site metastasis (radiotherapy+chemotherapy)—primary site-specific therapy takes priority. Neuroendocrine CUP: everolimus+octreotide, or etoposide+cisplatin (high grade).

In poor-prognosis CUP (the majority), carboplatin+paclitaxel or gemcitabine+cisplatin is used as empirical first-line chemotherapy. Molecular targeted therapy: MSI-H/dMMR — pembrolizumab monotherapy (FDA tumor-agnostic approval); TMB-H — pembrolizumab; NTRK fusion — larotrectinib/entrectinib; RET fusion — selpercatinib; BRAF V600E — dabrafenib+trametinib; HER2 amplification — trastuzumab-based regimens; BRCA1/2 mutation — olaparib (PARP inhibitor). Site-directed therapy based on molecular tissue-of-origin analysis is being evaluated in clinical trials (GEFCAPI, CUPISCO, etc.), with positive early results.

11. Prognosis

The overall prognosis of cancer of unknown primary is poor. The overall 5-year survival rate is around 10%, and median overall survival is 6–12 months with empirical chemotherapy. However, meaningful survival prolongation is possible in favorable-prognosis subsets. Favorable-prognosis subsets: squamous cell carcinoma CUP of the neck (5-year survival about 35–50%), neuroendocrine CUP (low grade, 5-year survival over 50%), peritoneal adenocarcinomatosis in women (similar prognosis when treated as ovarian cancer), extragonadal germ cell tumor (curable). Poor prognosis: adenocarcinoma CUP with multiple metastases, multiple metastases to liver, bone, lung and brain — median survival under 6 months.

By histologic type, squamous cell carcinoma CUP has a lower risk of death than adenocarcinoma CUP (HR 0.48). Response rates and survival improve in subsets amenable to molecular targeted therapy (MSI-H, TMB-H, NTRK fusion, etc.). With pembrolizumab monotherapy, an ORR of 20%, median progression-free survival of 4.1 months and median overall survival of 11.3 months (better than the overall CUP benchmark) have been reported. Site-directed therapy based on molecular tissue of origin is promising for improving prognosis, but results from large phase 3 randomized controlled trials have not yet sufficiently accumulated.

12. Prevention

There is no specific method of preventing cancer of unknown primary itself. Prevention of CUP is fundamentally achieved through prevention and early detection of common primary cancers. Participation in Korea's national screening program for the five major cancers (gastric cancer every 2 years, colorectal cancer annual fecal occult blood test + endoscopy every 5 years, liver cancer ultrasound and AFP every 6 months, cervical cancer every 2 years, breast cancer every 2 years) contributes to indirect prevention of CUP. Because smoking is an independent risk factor for CUP, smoking cessation is recommended. Excessive drinking, obesity and physical inactivity are also risk factors for various primary cancers, so improving them contributes indirectly to CUP prevention.

More important than direct prevention of CUP is a thorough diagnostic approach to find the primary lesion. The current clinical strategy is to reduce the proportion of CUP diagnoses themselves through active use of PET-CT, comprehensive genomic panels and molecular tissue-of-origin analysis, and, when the diagnosis is confirmed, to improve treatment outcomes by identifying targetable molecular alterations. HPV vaccination contributes to preventing HPV-related head and neck squamous cell carcinoma—some of which are classified as CUP. In carriers of hereditary cancer syndromes (Lynch syndrome, BRCA1/2 mutations, etc.), early preventive treatment and regular screening allow early detection of primary cancers that could develop into CUP.


13. References

  1. Krämer A, et al. Cancer of unknown primary — ESMO Clinical Practice Guideline 2023. Ann Oncol. 2023;34(3):228-246.
  2. Cancer of unknown primary — epidemiological trends and CGP. PMC. 2018;PMC6144156.
  3. Efficacy of pembrolizumab in CUP — phase 2 trial. PMC. 2022;PMC9125753.
  4. NCI. Cancer of Unknown Primary Treatment (PDQ®). 2024.
  5. Squamous CUP — genomic landscape study. ESMO Open. 2025.
  6. UCSF Hospital Handbook. Cancer of Unknown Primary Site. 2025.
  7. National Cancer Information Center. Information on cancer of unknown primary. 2024.
  8. Fizazi K, et al. Specific cancer treatment according to tumor gene expression in CUP — CUPISCO trial. J Clin Oncol. 2023.